- Home
- CODA vs CLYM Comparison
CODA vs CLYM Comparison
Compare CODA & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- CLYM
- Stock Information
- Founded
- CODA 1994
- CLYM 2018
- Country
- CODA United States
- CLYM United States
- Employees
- CODA N/A
- CLYM N/A
- Industry
- CODA Industrial Machinery/Components
- CLYM
- Sector
- CODA Industrials
- CLYM
- Exchange
- CODA Nasdaq
- CLYM NYSE
- Market Cap
- CODA 88.7M
- CLYM 87.8M
- IPO Year
- CODA N/A
- CLYM 2021
- Fundamental
- Price
- CODA $8.11
- CLYM $1.28
- Analyst Decision
- CODA Strong Buy
- CLYM Buy
- Analyst Count
- CODA 1
- CLYM 1
- Target Price
- CODA $11.00
- CLYM $10.00
- AVG Volume (30 Days)
- CODA 62.6K
- CLYM 412.0K
- Earning Date
- CODA 06-16-2025
- CLYM 08-13-2025
- Dividend Yield
- CODA N/A
- CLYM N/A
- EPS Growth
- CODA 21.86
- CLYM N/A
- EPS
- CODA 0.30
- CLYM N/A
- Revenue
- CODA $22,758,966.00
- CLYM N/A
- Revenue This Year
- CODA $11.64
- CLYM N/A
- Revenue Next Year
- CODA $14.53
- CLYM N/A
- P/E Ratio
- CODA $27.03
- CLYM N/A
- Revenue Growth
- CODA 24.78
- CLYM N/A
- 52 Week Low
- CODA $5.76
- CLYM $1.05
- 52 Week High
- CODA $9.89
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- CODA 61.67
- CLYM N/A
- Support Level
- CODA $7.78
- CLYM N/A
- Resistance Level
- CODA $8.31
- CLYM N/A
- Average True Range (ATR)
- CODA 0.57
- CLYM 0.00
- MACD
- CODA 0.05
- CLYM 0.00
- Stochastic Oscillator
- CODA 60.98
- CLYM 0.00
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.